Semorelin — Research Summary

Research Use Only · Not for Human or Veterinary Use

GHRH analog consisting of the first 29 amino acids of endogenous GHRH, studied f

Semorelin

An evidence summary of published preclinical research on Semorelin. This page is educational and summarizes findings reported in third-party scientific literature. No claims are made regarding safety or efficacy in humans.

Molecular Data

FORMULA C149H246N44O42S
MOLECULAR WEIGHT 3,357.88 g/mol
SEQUENCE Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NHâ‚‚

Compound Overview

Sermorelin (also commonly spelled Semorelin) is a synthetic peptide consisting of the first 29 amino acids of the 44-amino acid sequence of human growth hormone-releasing hormone (GHRH). It was one of the first GHRH analogs developed and was previously FDA-approved (as Geref) for diagnostic evaluation of pituitary GH secretion capacity. It stimulates natural, pulsatile GH release from the anterior pituitary.

Reported Mechanism (Preclinical)

Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, activating adenylyl cyclase through Gs-protein coupling and increasing intracellular cAMP. This triggers calcium influx and subsequent GH exocytosis. Importantly, the GH release maintains physiological pulsatility and is subject to normal feedback regulation by somatostatin and IGF-1, reducing the risk of supraphysiological GH levels.

Mechanisms described above are reported in preclinical (animal and in vitro) literature and have not been established for human use.

Key Research Highlights

  • Restored pulsatile GH secretion patterns in GH-deficient adults in clinical studies (Vittone et al., 1997)
  • Improved body composition (decreased fat mass, increased lean mass) in aging populations over 6 months
  • Enhanced slow-wave (deep) sleep duration and quality in clinical sleep studies
  • Maintained physiological negative feedback, preventing GH excess
  • Demonstrated favorable long-term safety profile across multiple clinical studies

Published References

  1. Sermorelin: a review of its use in the diagnosis and treatment of GH deficiency
    BioDrugs, 2002
  2. Effects of GHRH on sleep and GH secretion in healthy aged men
    Am J Physiol, 1997
  3. Growth hormone-releasing hormone analog treatment in aging adults
    J Clin Endocrinol Metab, 2009

Available for Research

Lab-tested, third-party COA published, U.S. ships same day.

View Product · Semorelin View COA Library
Compliance Notice: American Peptides products are sold strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature, summarizes findings from preclinical literature, and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution's safety protocols and applicable laws.